| 0 (0%) | 09-27 09:34 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.51 |
1-year : | 8.77 |
| Resists | First : | 6.42 |
Second : | 7.51 |
| Pivot price | 5.15 |
|||
| Supports | First : | 4.76 |
Second : | 3.73 |
| MAs | MA(5) : | 5.4 |
MA(20) : | 4.96 |
| MA(100) : | 3.77 |
MA(250) : | 3.71 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 60.5 |
D(3) : | 60.7  |
| RSI | RSI(14): 68.4 |
|||
| 52-week | High : | 6.42 | Low : | 2.11 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AQST ] has closed above the upper band by 16.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 23.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.43 - 6.47 | 6.47 - 6.49 |
| Low: | 5.73 - 5.76 | 5.76 - 5.79 |
| Close: | 5.94 - 5.99 | 5.99 - 6.04 |
Sat, 27 Sep 2025
Is AQST a good long term investment - Market Breadth Indicators & Free Stock Predictions and Analysis - Early Times
Fri, 26 Sep 2025
Aquestive Therapeutics (NASDAQ:AQST) Hits New 52-Week High - Time to Buy? - MarketBeat
Fri, 26 Sep 2025
Why Aquestive Therapeutics Stock Jumped After-Hours Today - Stocktwits
Thu, 25 Sep 2025
Mixed Catalysts Drive After-Hours Moves In MRM, LEXX, SHOT, AQST, And OVID - Nasdaq
Wed, 24 Sep 2025
Aquestive Therapeutics (AQST) Is Up 6.8% After FDA Clears Path for Needle-Free Epinephrine Film Approval - simplywall.st
Tue, 23 Sep 2025
ARS Pharma Urges FDA To Delay Approval Of Aquestive's Allergic Reaction Treatment - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 121 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 4.1 (%) |
| Held by Institutions | 42.4 (%) |
| Shares Short | 9,270 (K) |
| Shares Short P.Month | 9,440 (K) |
| EPS | -0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.74 |
| Profit Margin | -147.4 % |
| Operating Margin | -113.7 % |
| Return on Assets (ttm) | -31.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -50.3 % |
| Gross Profit (p.s.) | 0.22 |
| Sales Per Share | 0.36 |
| EBITDA (p.s.) | -0.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -8.69 |
| PEG Ratio | 0 |
| Price to Book value | -8.21 |
| Price to Sales | 16.41 |
| Price to Cash Flow | -14.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|